ANI Pharmaceuticals (NASDAQ:ANIP) Research Coverage Started at Piper Sandler

Piper Sandler started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report sent to investors on Friday, Marketbeat Ratings reports. The firm issued an overweight rating and a $68.00 price target on the specialty pharmaceutical company’s stock.

Several other brokerages have also commented on ANIP. Raymond James upped their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an outperform rating in a research report on Wednesday, September 18th. HC Wainwright reiterated a buy rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Tuesday, September 17th. StockNews.com downgraded shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, September 7th. Finally, Truist Financial reissued a hold rating and set a $60.00 price target (down from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $77.00.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $57.14 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 35.71 and a beta of 0.71. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average is $59.43 and its two-hundred day moving average is $62.62. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The company had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period in the prior year, the firm earned $1.06 EPS. The firm’s quarterly revenue was up 18.5% on a year-over-year basis. Research analysts expect that ANI Pharmaceuticals will post 3.58 EPS for the current year.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total transaction of $900,472.12. Following the sale, the chief operating officer now directly owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 14,757 shares of company stock valued at $929,582. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently modified their holdings of the company. Innealta Capital LLC acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $65,000. Ridgewood Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $85,000. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $106,000. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $207,000. Finally, O Shaughnessy Asset Management LLC bought a new position in ANI Pharmaceuticals in the 1st quarter valued at about $218,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.